1.43 USD
+0.02 (+1.42%)
We assign a fundamental rating of 3 out of 10 to SNGX. SNGX was compared to 530 industry peers in the Biotechnology industry. The financial health of SNGX is average, but there are quite some concerns on its profitability. SNGX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year SNGX has reported negative net income.
SNGX had a negative operating cash flow in the past year.
In the past 5 years SNGX always reported negative net income.
In the past 5 years SNGX always reported negative operating cash flow.
1.2 Ratios
SNGX has a Return On Assets of -101.45%. This is in the lower half of the industry: SNGX underperforms 75.09% of its industry peers.
SNGX has a worse Return On Equity (-150.79%) than 63.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.45% | ||
| ROE | -150.79% | ||
| ROIC | N/A |
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNGX has been increased compared to 1 year ago.
Compared to 5 years ago, SNGX has more shares outstanding
Compared to 1 year ago, SNGX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -30.53, we must say that SNGX is in the distress zone and has some risk of bankruptcy.
SNGX has a Altman-Z score of -30.53. This is amonst the worse of the industry: SNGX underperforms 87.36% of its industry peers.
There is no outstanding debt for SNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -30.53 |
ROIC/WACCN/A
WACC8.96%
2.3 Liquidity
A Current Ratio of 3.18 indicates that SNGX has no problem at all paying its short term obligations.
With a Current ratio value of 3.18, SNGX is not doing good in the industry: 62.08% of the companies in the same industry are doing better.
SNGX has a Quick Ratio of 3.18. This indicates that SNGX is financially healthy and has no problem in meeting its short term obligations.
SNGX's Quick ratio of 3.18 is in line compared to the rest of the industry. SNGX outperforms 40.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.18 | ||
| Quick Ratio | 3.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.38% over the past year.
The Revenue for SNGX has decreased by -100.00% in the past year. This is quite bad
Measured over the past years, SNGX shows a very negative growth in Revenue. The Revenue has been decreasing by -51.88% on average per year.
EPS 1Y (TTM)58.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.64%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, SNGX will show a very strong growth in Earnings Per Share. The EPS will grow by 23.29% on average per year.
Based on estimates for the next years, SNGX will show a small growth in Revenue. The Revenue will grow by 6.88% on average per year.
EPS Next Y64.11%
EPS Next 2Y36.53%
EPS Next 3Y23.29%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y10.5%
Revenue Next 3Y6.88%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SNGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNGX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SNGX's earnings are expected to grow with 23.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.53%
EPS Next 3Y23.29%
5. Dividend
5.1 Amount
No dividends for SNGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:SNGX (1/7/2026, 11:03:36 AM)
1.43
+0.02 (+1.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners13.78%
Inst Owner Change0%
Ins Owners0.16%
Ins Owner Change0.5%
Market Cap14.43M
Revenue(TTM)N/A
Net Income(TTM)-11.46M
Analysts82.86
Price Target17.85 (1148.25%)
Short Float %5.1%
Short Ratio1.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.08%
Min EPS beat(2)-2.46%
Max EPS beat(2)12.62%
EPS beat(4)1
Avg EPS beat(4)-15.65%
Min EPS beat(4)-55.11%
Max EPS beat(4)12.62%
EPS beat(8)4
Avg EPS beat(8)-1.7%
EPS beat(12)7
Avg EPS beat(12)-11.59%
EPS beat(16)9
Avg EPS beat(16)-10.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.22%
EPS NQ rev (1m)-51.35%
EPS NQ rev (3m)-3.7%
EPS NY rev (1m)9.47%
EPS NY rev (3m)23.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.9 | ||
| P/tB | 1.9 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.6
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0
BVpS0.75
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.45% | ||
| ROE | -150.79% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.18 | ||
| Quick Ratio | 3.18 | ||
| Altman-Z | -30.53 |
F-Score3
WACC8.96%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.64%
EPS Next Y64.11%
EPS Next 2Y36.53%
EPS Next 3Y23.29%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y10.5%
Revenue Next 3Y6.88%
Revenue Next 5YN/A
EBIT growth 1Y-57.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.3%
OCF growth 3YN/A
OCF growth 5YN/A
SOLIGENIX INC / SNGX FAQ
Can you provide the ChartMill fundamental rating for SOLIGENIX INC?
ChartMill assigns a fundamental rating of 3 / 10 to SNGX.
What is the valuation status of SOLIGENIX INC (SNGX) stock?
ChartMill assigns a valuation rating of 1 / 10 to SOLIGENIX INC (SNGX). This can be considered as Overvalued.
What is the profitability of SNGX stock?
SOLIGENIX INC (SNGX) has a profitability rating of 0 / 10.
Can you provide the financial health for SNGX stock?
The financial health rating of SOLIGENIX INC (SNGX) is 6 / 10.
What is the earnings growth outlook for SOLIGENIX INC?
The Earnings per Share (EPS) of SOLIGENIX INC (SNGX) is expected to grow by 64.11% in the next year.